Trial Profile

Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 18 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonidegib (Primary) ; Bortezomib
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

10 Dec 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
27 Aug 2015 Planned End Date changed from 1 Oct 2019 to 1 Sep 2020 as reported by ClinicalTrials.gov record.
27 Aug 2015 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com